HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 282, Issue 26, 18819-18830, June 29, 2007

This Article Full Text Full Text (PDF) All Versions of this Article: 282/26/18819    most recent M610537200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yano, N. Articles by Tseng, Y.-T. Search for Related Content PubMed PubMed Citation Articles by Yano, N. Articles by Tseng, Y.-T. Social Bookmarking                      What's this?

A Novel Phosphoinositide 3-Kinase-dependent Pathway for Angiotensin II/AT-1 Receptor-mediated Induction of Collagen Synthesis in MES-13 Mesangial Cells^*

Naohiro Yano, Daisuke Suzuki, Masayuki Endoh, Ting C. Zhao, James F. Padbury, and Yi-Tang Tseng¹

From the Department of Pediatrics, Women & Infant's Hospital, The Warren Alpert Medical School, Brown University, Providence, Rhode Island 02905 and the Division of Nephrology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan

Chronic activation of the angiotensin II (ANG II) type 1 receptor (AT-1R) is critical in the development of chronic kidney disease. ANG II activates mesangial cells (MCs) and stimulates the synthesis of extracellular matrix components. To determine the molecular mechanisms underlying the induction of MC collagen, a mouse mesangial cell line MES-13 was employed. ANG II treatment induced an increase in collagen synthesis, which was abrogated by co-treatment with losartan (an AT-1R antagonist), wortmannin (a phosphoinositide 3-kinase (PI3K) inhibitor), an Akt inhibitor, and stable transfection of dominant negative-Akt1. ANG II induced a significant increase in PI3K activity, which was abolished by co-treatment with losartan or 2',5'-dideoxyadenosine (2',5'-DOA, an adenylyl cyclase inhibitor) but not by PD123319 (an AT-2R antagonist) or H89 (a protein kinase A (PKA) inhibitor). The Epac (exchange protein directly activated by cAMP)-specific cAMP analog, 8-pHPT-2'-O-Me-cAMP, significantly increased PI3K activity, whereas a PKA-specific analog, 6-benzoyladenosine-cAMP, showed no effect. The ANG II-induced increase in PI3K activity was also blocked by co-treatment with PP2, an Src inhibitor, or AG1478, an epidermal growth factor receptor (EGFR) antagonist. ANG II induced phosphorylation of Akt and p70S6K and EGFR, which was abrogated by knockdown of c-Src by small interference RNA. Knockdown of Src also effectively abolished ANG II-induced collagen synthesis. Conversely, stable transfection of a constitutively active Src mutant enhanced basal PI3K activity and collagen production, which was abrogated by AG1478 but not by 2',5'-DOA. Moreover, acute treatment with ANG II significantly increased Src activity, which was abrogated with co-treatment of 2',5'-DOA. Taken together, these results suggest that ANG II induces collagen synthesis in MCs by activating the ANG II/AT-1R-EGFR-PI3K pathway. This transactivation is dependent on cAMP/Epac but not on PKA. Src kinase plays a pivotal role in this signaling pathway between cAMP and EGFR. This is the first demonstration that an AT1R-PI3K/Akt crosstalk, along with transactivation of EGFR, mediates ANG II-induced collagen synthesis in MCs.

Received for publication, November 13, 2006 , and in revised form, April 18, 2007.

^* This work was supported by National Institutes of Health Grant 1 P20 RR018728. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed: Dept. of Pediatrics, Women and Infant's Hospital, 101 Dudley St., Kilguss 122, Providence, RI 02905. Tel.: 401-274-1122 (ext. 8006); Fax: 401-277-3617; E-mail: YTseng{at}wihri.org.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Gates, S. Hohenester, M. S. Anwer, and C. R. L. Webster cAMP-GEF cytoprotection by Src tyrosine kinase activation of phosphoinositide-3-kinase p110 {beta}/{alpha} in rat hepatocytes Am J Physiol Gastrointest Liver Physiol, April 1, 2009; 296(4): G764 - G774. [Abstract] [Full Text] [PDF]

				N. Yano, D. Suzuki, M. Endoh, A. Tseng, J. P. Stabila, B. G. McGonnigal, T. C. Zhao, J. F. Padbury, and Y.-T. Tseng {beta}-Adrenergic Receptor Mediated Protection against Doxorubicin-Induced Apoptosis in Cardiomyocytes: The Impact of High Ambient Glucose Endocrinology, December 1, 2008; 149(12): 6449 - 6461. [Abstract] [Full Text] [PDF]

				K. Block, A. Eid, K. K. Griendling, D.-Y. Lee, Y. Wittrant, and Y. Gorin Nox4 NAD(P)H Oxidase Mediates Src-dependent Tyrosine Phosphorylation of PDK-1 in Response to Angiotensin II: ROLE IN MESANGIAL CELL HYPERTROPHY AND FIBRONECTIN EXPRESSION J. Biol. Chem., August 29, 2008; 283(35): 24061 - 24076. [Abstract] [Full Text] [PDF]

				Y. Li, I. B. M. Konings, J. Zhao, L. S. Price, E. de Heer, and P. M. T. Deen Renal expression of exchange protein directly activated by cAMP (Epac) 1 and 2 Am J Physiol Renal Physiol, August 1, 2008; 295(2): F525 - F533. [Abstract] [Full Text] [PDF]